Biparametric MRI (bpMRI), which excludes dynamic contrast-enhanced sequences, is noninferior to multiparametric MRI (mpMRI) in diagnosing clinically significant prostate cancer.
The PRIME trial, a large-scale, multicenter prospective study involving 490 biopsy-naive men with suspected prostate cancer, confirmed bpMRI’s diagnostic accuracy closely matches mpMRI.
Biparametric MRI offers substantial resource and time savings, potentially increasing global MRI throughput and reducing costs for prostate cancer diagnosis.
